Construction And Evaluation Of China's Advanced Pancreatic Tumor Big Data Center

Study Overview

Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

This study is a multi-center observational study. The start time for data collection is August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. Patients' baseline and treatment data will be collected under informed concent. The combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.

N/A

Pancreatic Neoplasms

OTHER: No intervention will be considered in this study.

CPOG-CDPC-01

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2021-11-20	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2021-11-20
First Submitted that Met QC Criteria 2021-11-20	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2021-12-02
First Posted (ACTUAL) 2021-12-02	Results First Posted N/A	Last Verified 2021-11

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: Single arm Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent.	OTHER: No intervention will be considered in this study. No intervention will be considered in this study.

Participant Group/Arm

Intervention/Treatment

: Single arm

Patients diagnosed as pancreatic tumor will considered to be enrolled regardless of specific pathologic subtypes expect for metastasis of pancreas. Baseline data and treatment information will be collected under fully informed consent.

OTHER: No intervention will be considered in this study.

No intervention will be considered in this study.

Primary Outcome Measures	Measure Description	Time Frame
OS	overall survival	5 years

Secondary Outcome Measures	Measure Description	Time Frame
DFS	disease free survival	5 years
PFS	progress free survival	5 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record